dermaPACE® Phase III Trial Results Announced
View Technology Details, Study Design and 24-Week Top-Line Safety and Efficacy Results of SANUWAVE’s Randomized,
Double-blinded, Sham-controlled, Pivotal Clinical Trial
View Technology Details, Study Design and 24-Week Top-Line Safety and Efficacy Results of SANUWAVE’s Randomized,
Double-blinded, Sham-controlled, Pivotal Clinical Trial
News
Jan 25, 2012 - SANUWAVE Technology Shown to Promote Fracture Healing by Affecting Growth of New Blood Vessels and Bone
Jan 17, 2012 - SANUWAVE Issued U.S. Patent for a New Method to Produce Acoustic Shock Waves Utilizing Pressurized Fluid
Jan 10, 2012 - PACE Technology Shown to Protect Tissues Against Ischemic and Reperfusion Injury
Jan 25, 2012 - SANUWAVE Technology Shown to Promote Fracture Healing by Affecting Growth of New Blood Vessels and Bone
Jan 17, 2012 - SANUWAVE Issued U.S. Patent for a New Method to Produce Acoustic Shock Waves Utilizing Pressurized Fluid
Jan 10, 2012 - PACE Technology Shown to Protect Tissues Against Ischemic and Reperfusion Injury
About SANUWAVE
A pioneer in the field of regenerative medicine, SANUWAVE specializes in the development and commercialization of
non-invasive, biological response activating devices based on the PACE® Technology platform.
Learn more about ESWT and PACE Science
A pioneer in the field of regenerative medicine, SANUWAVE specializes in the development and commercialization of
non-invasive, biological response activating devices based on the PACE® Technology platform.
Learn more about ESWT and PACE Science